17.77 USD
-0.05 (-0.28%)
17.7873 USD
+0.02 (+0.1%)
Overall ZLAB gets a fundamental rating of 3 out of 10. We evaluated ZLAB against 529 industry peers in the Biotechnology industry. Both the profitability and financial health of ZLAB have multiple concerns. ZLAB is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ZLAB had negative earnings in the past year.
In the past year ZLAB has reported a negative cash flow from operations.
In the past 5 years ZLAB always reported negative net income.
ZLAB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -18.26%, ZLAB is doing good in the industry, outperforming 77.40% of the companies in the same industry.
Looking at the Return On Equity, with a value of -26.84%, ZLAB is in the better half of the industry, outperforming 78.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.26% | ||
| ROE | -26.84% | ||
| ROIC | N/A |
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ZLAB (62.46%) is better than 78.72% of its industry peers.
ZLAB's Gross Margin has declined in the last couple of years.
ZLAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
2. Health
2.1 Basic Checks
ZLAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZLAB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ZLAB has more shares outstanding
ZLAB has a worse debt/assets ratio than last year.
2.2 Solvency
ZLAB has an Altman-Z score of 0.50. This is a bad value and indicates that ZLAB is not financially healthy and even has some risk of bankruptcy.
ZLAB has a better Altman-Z score (0.50) than 60.45% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that ZLAB is not too dependend on debt financing.
The Debt to Equity ratio of ZLAB (0.22) is worse than 67.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.5 |
ROIC/WACCN/A
WACC7.37%
2.3 Liquidity
A Current Ratio of 3.12 indicates that ZLAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.12, ZLAB is doing worse than 63.65% of the companies in the same industry.
ZLAB has a Quick Ratio of 2.93. This indicates that ZLAB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ZLAB (2.93) is worse than 63.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.93 |
3. Growth
3.1 Past
ZLAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.63%, which is quite impressive.
Looking at the last year, ZLAB shows a very strong growth in Revenue. The Revenue has grown by 49.59%.
The Revenue has been growing by 98.34% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)29.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)49.59%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%13.27%
3.2 Future
ZLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 81.52% yearly.
Based on estimates for the next years, ZLAB will show a very strong growth in Revenue. The Revenue will grow by 37.92% on average per year.
EPS Next Y33.21%
EPS Next 2Y32.53%
EPS Next 3Y32.41%
EPS Next 5Y81.52%
Revenue Next Year31.31%
Revenue Next 2Y33%
Revenue Next 3Y37.61%
Revenue Next 5Y37.92%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ZLAB. In the last year negative earnings were reported.
Also next year ZLAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ZLAB's earnings are expected to grow with 32.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.53%
EPS Next 3Y32.41%
5. Dividend
5.1 Amount
ZLAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
17.77
-0.05 (-0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners34.49%
Inst Owner Change-10.3%
Ins Owners1.73%
Ins Owner Change23.75%
Market Cap1.97B
Revenue(TTM)398.99M
Net Income(TTM)-212.52M
Analysts78.57
Price Target24.38 (37.2%)
Short Float %4.5%
Short Ratio5.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)1.96%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)15.62%
Min EPS beat(4)-12.04%
Max EPS beat(4)50.98%
EPS beat(8)6
Avg EPS beat(8)16.58%
EPS beat(12)9
Avg EPS beat(12)32.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.38%
Min Revenue beat(2)-14.17%
Max Revenue beat(2)-10.58%
Revenue beat(4)0
Avg Revenue beat(4)-7.13%
Min Revenue beat(4)-14.17%
Max Revenue beat(4)-1.65%
Revenue beat(8)3
Avg Revenue beat(8)-2.39%
Revenue beat(12)5
Avg Revenue beat(12)-2.09%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.03%
PT rev (3m)-29.69%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-9.42%
EPS NY rev (1m)-18.13%
EPS NY rev (3m)-19.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.42%
Revenue NY rev (1m)-7.47%
Revenue NY rev (3m)-8.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.48 | ||
| P/tB | 2.68 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.88
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS3.87
BVpS7.16
TBVpS6.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.26% | ||
| ROE | -26.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.46% | ||
| FCFM | N/A |
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
F-Score4
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 425.16% | ||
| Cap/Sales | 13.02% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.93 | ||
| Altman-Z | 0.5 |
F-Score4
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)305.55%
Cap/Depr(5y)287.72%
Cap/Sales(3y)10.07%
Cap/Sales(5y)13.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y33.21%
EPS Next 2Y32.53%
EPS Next 3Y32.41%
EPS Next 5Y81.52%
Revenue 1Y (TTM)49.59%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%13.27%
Revenue Next Year31.31%
Revenue Next 2Y33%
Revenue Next 3Y37.61%
Revenue Next 5Y37.92%
EBIT growth 1Y30.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.86%
EBIT Next 3Y31.7%
EBIT Next 5Y32.27%
FCF growth 1Y39.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.78%
OCF growth 3YN/A
OCF growth 5YN/A
ZAI LAB LTD-ADR / ZLAB FAQ
Can you provide the ChartMill fundamental rating for ZAI LAB LTD-ADR?
ChartMill assigns a fundamental rating of 3 / 10 to ZLAB.
Can you provide the valuation status for ZAI LAB LTD-ADR?
ChartMill assigns a valuation rating of 1 / 10 to ZAI LAB LTD-ADR (ZLAB). This can be considered as Overvalued.
How profitable is ZAI LAB LTD-ADR (ZLAB) stock?
ZAI LAB LTD-ADR (ZLAB) has a profitability rating of 2 / 10.
What is the expected EPS growth for ZAI LAB LTD-ADR (ZLAB) stock?
The Earnings per Share (EPS) of ZAI LAB LTD-ADR (ZLAB) is expected to grow by 33.21% in the next year.